%0 Journal Article
%T Impact of efavirenz on hormone-positive breast cancer survival in women living with HIV.
%A Johnson AT
%A Ntloedibe T
%A Mendez Reyes JE
%A Matshaba MS
%A Dryden-Peterson SL
%A Chiao EY
%J AIDS
%V 38
%N 9
%D 2024 07 15
%M 38932749
%F 4.632
%R 10.1097/QAD.0000000000003912
%X Women living with HIV and breast cancer have poorer survival than HIV-negative women. Efavirenz-estrogen interactions are documented; however, the survival impact is unknown. Survival between women with estrogen-receptor positive breast cancer taking efavirenz (n = 38) and nonefavirenz regimens (n = 51) were compared. The 5-year overall-survival was 48.9% [95% confidence interval (CI) 33.0-72.2 and 51.1% (95% CI 34.0-76.8)] in the efavirenz and nonefavirenz groups, respectively suggesting efavirenz is unlikely driving poorer survival in women living with HIV and estrogen-receptor positive breast cancer.